DelveInsight’s “Cushing’s Syndrome Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Cushing’s Syndrome pipeline landscapes. It comprises Cushing’s Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cushing’s Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cushing’s Syndrome pipeline products.
Some of the key takeaways of the Cushing’s Syndrome Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, etc., are developing therapies for the treatment of Cushing’s Syndrome.
Emerging therapies such as Osilodrostat, Relacorilant, ATR-101, Levoketoconazole, ST-002, are expected to have a significant impact on the Cushing’s Syndrome market in the coming years.
Osilodrostat is an orally administered steroidogenesis inhibitor of 11Beta-hydroxylase, an enzyme that catalyses the final step of cortisol synthesis in the adrenal cortex. This molecule is currently in Phase III of clinical development.
Get an overview of pipeline landscape @ Cushing’s Syndrome Clinical Trials Analysis
Cushing’s syndrome (CS) is a rare problem caused when the adrenal gland(s) makes too much of a hormone called cortisol. CS is most often due to a tumour or mass found in the pituitary gland, but can also be caused by tumours in the adrenal glands themselves.
Cushing’s Syndrome Emerging Drugs
Osilodrostat by Recordati
Relacorilant by Corcept Therapeutics
ATR-101 by Millendo Therapeutics
Levoketoconazole by Cortendo
ST-002 by SteroTherapeutics
For further information, refer to the detailed report @ Cushing’s Syndrome Pipeline Therapeutics
Scope of Cushing’s Syndrome Pipeline Drug Insight
Coverage: Global
Major Players: Recordati, Corcept Therapeutics, Millendo Therapeutics, Cortendo, SteroTherapeutics, and others.
Pipeline Therapies: Osilodrostat, Relacorilant, ATR-101, Levoketoconazole, ST-002, and others.
Table of Contents
1
Cushing’s Syndrome Report Introduction
2
Cushing’s Syndrome Executive Summary
3
Cushing’s Syndrome Overview
4
Cushing’s Syndrome- Analytical Perspective In-depth Commercial Assessment
5
Cushing’s Syndrome Pipeline Therapeutics
6
Cushing’s Syndrome Late Stage Products (Phase II/III)
7
Cushing’s Syndrome Mid Stage Products (Phase II)
8
Cushing’s Syndrome Early Stage Products (Phase I)
9
Cushing’s Syndrome Preclinical Stage Products
10
Cushing’s Syndrome Therapeutic Assessment
11
Cushing’s Syndrome Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Cushing’s Syndrome Key Companies
14
Cushing’s Syndrome Key Products
15
Cushing’s Syndrome Unmet Needs
16
Cushing’s Syndrome Market Drivers and Barriers
17
Cushing’s Syndrome Future Perspectives and Conclusion
18
Cushing’s Syndrome Analyst Views
19
Appendix
20
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/